Form 4: Glaukos Director Marc Stapley Receives Equity Grant

Director Marc Stapley acquired 1,878 restricted stock units and 2,987 stock options as part of the Glaukos Corporation director compensation policy.

Summary

• Director Marc Stapley was granted 1,878 restricted stock units (RSUs) on May 28, 2026.
• The director also received 2,987 stock options with an exercise price of $53.57.
• The RSUs and options vest in full on the one-year anniversary of the grant date, May 28, 2027.
• Following these transactions, the director's total beneficial ownership of common stock is 39,327 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Equity-based compensation aligns the director's interests with long-term shareholder value.
• The grant is part of a standard, pre-established director compensation policy.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the ultimate value of the granted equity instruments.

Future Outlook

The equity grants are subject to a one-year vesting period, indicating the director's continued service through May 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the medical device industry to ensure alignment with long-term strategic goals.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap medical technology companies.
• The one-year cliff vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on May 28, 2027.

Key Dates

Keywords

Glaukos, GKOS, Director Compensation, Form 4, Insider Trading, Equity Grant